RT Journal Article SR Electronic T1 ddPCR Reveals SARS-CoV-2 Variants in Florida Wastewater JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.04.08.21255119 DO 10.1101/2021.04.08.21255119 A1 Eben Gering A1 Jacob Colbert A1 Sarah Schmedes A1 George Duncan A1 Joe Lopez A1 Jessy Motes A1 James Weiss A1 Taj Azarian A1 Omer Tekin A1 Jason Blanton YR 2021 UL http://medrxiv.org/content/early/2021/04/13/2021.04.08.21255119.abstract AB Wastewater was screened for the presence of functionally significant mutations in SARS-CoV-2 associated with emerging variants of concern (VOC) by ddPCR, and results accorded with sequencing of clinical samples from the same region. We propose that PCR-based screening of wastewater can provide a powerful tool for rapid and inexpensive screening of large population segments for VOC-associated mutations and can hone complementary sampling and sequencing of direct (human) test material to track emerging VOC.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe study includes cited data from routine surveillance of clinical samples conducted by Florida Department of Health.Funding StatementFunding was provided via a CDC epidemiology and laboratory capacity grant (ELC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB was required for this testing.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRelevent data are contained within the manuscript and SARS-CoV-2 consensus assemblies for clinical samples with N501Y and/or S69-70del mutations are available on NCBI Genbank, with accession IDs listed in the method section of the paper.